Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Biotech

Biotech

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • General
  • Legal
  • News

Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit

By Benzinga Newsdesk
May 14, 9:03 AM
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute

SCLX

Read More
1 minute read
  • Biotech
  • General
  • News

GE HealthCare, Medis Medical Imaging Collaborate To Focus On Non-Invasive Coronary Assessments To Help Advance Precision Care In Treatment Of Coronary Artery Disease

By Benzinga Newsdesk
May 14, 9:01 AM
Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology.Both companies will focus on the integration of Medis QFR into GE HealthCare's

GEHC

Read More
1 minute read
  • Biotech
  • General
  • News

CENTOGENE And Evotec Announce Discovery Of New Molecule To Treat Gaucher Disease

By Benzinga Newsdesk
May 14, 8:53 AM
CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon

CNTG

Read More
1 minute read
  • Biotech
  • General
  • News

Fortress Biotech Doses First Paitent In Multi-Center Phase 2 Study Of Triplex For Control Of Cytomegalovirus In Patients Undergoing Liver Transplantation

By Benzinga Newsdesk
May 14, 8:45 AM
Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical trial funded by a

FBIO

Read More
1 minute read
  • Biotech
  • General
  • News

Neurocrine Biosciences Presents Data At ECE 2024, The CAHtalyst Program In Congenital Adrenal Hyperplasia And Study Data For Modified-Release Hydrocortisone In Primary Adrenal Insufficiency And CAH

By Benzinga Newsdesk
May 14, 8:43 AM
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults- Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal

NBIX

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News

Novo Nordisk’s Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments

By Benzinga Neuro
May 14, 2:26 AM
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug.

NONOF

Read More
2 minute read
  • Biotech
  • Cannabis
  • Emerging Markets
  • Entrepreneurship
  • ESG
  • General
  • Markets
  • News

Coca-Cola, PepsiCo And Nestlé Are Top Plastic Polluters: Is Hemp The Answer To Nanoplastics In The Oceans??

By Nicolas Jose Rodriguez
May 13, 6:25 PM
According to a new study published in Science Advances, fifty-six brands led by Coca-Cola (NYSE: KO), PepsiCo (NASDAQ: PEP), and Nestlé (SWX: NESN) are responsible for more

KO

Read More
2 minute read
  • After-Hours Center
  • Biotech
  • Earnings
  • Health Care
  • Movers
  • News

Vaxart Stock Climbs After Blockbuster Q1 Revenue

By Erica Kollmann
May 13, 4:29 PM
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.

VXRT

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Large Cap
  • News
  • Top Stories

Johnson & Johnson’s Subsidiary Discontinues Some Megadyne Electrodes For Pediatric Use

By Vandana Singh
May 13, 2:30 PM
Johnson & Johnson's Megadyne Mega Soft Pediatric Patient Return Electrodes recalled due to patient burns. FDA's Class I recall impacts 21,200 devices.

JNJ

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Top Stories

Why Is Inventiva’s Stock Trading Higher on Monday?

By Vandana Singh
May 13, 2:08 PM
Inventiva's Lanifibranor improves cardiometabolic health in MASH/NASH patients. It lowers fasting glucose, reduces cardiovascular risk, and increases adiponectin levels. Weight gain correlates with health improvement.

IVA

Posts pagination

Previous 1 … 32 33 34 … 733 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service